Corifollitropin Alfa + Follitropin beta + oral contraceptive pill pretreatment (Marvelon)
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Infertility, Female
Conditions
Infertility, Female, Polycystic Ovary Syndrome
Trial Timeline
Nov 1, 2017 → Dec 31, 2022
NCT ID
NCT03197077About Corifollitropin Alfa + Follitropin beta + oral contraceptive pill pretreatment (Marvelon)
Corifollitropin Alfa + Follitropin beta + oral contraceptive pill pretreatment (Marvelon) is a phase 3 stage product being developed by Merck for Infertility, Female. The current trial status is completed. This product is registered under clinical trial identifier NCT03197077. Target conditions include Infertility, Female, Polycystic Ovary Syndrome.
What happened to similar drugs?
11 of 20 similar drugs in Infertility, Female were approved
Approved (11) Terminated (4) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03197077 | Phase 3 | Completed |
Competing Products
20 competing products in Infertility, Female